Trials
3 active
6 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Colorectal Neoplasms (2 trials), Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Advanced Neoplasms, Solid Neoplasms, Gastrointestinal Tumors
- Main trialPhase 1/2
- “The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).”In the company’s words, NCT04008797 on ClinicalTrials.gov
Other drugs for Colorectal Neoplasms
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up3
- 31 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Mar 2027 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | |
| Phase 1Active, not recruiting | 31 Mar 2027 | Study of E7386 in Participants With Selected Advanced Neoplasms | |
| Phase 1Active, not recruiting | 31 Mar 2027 | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | |
| Phase 1/2Completed | 15 Oct 2024 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | |
| Phase 1Withdrawn | 17 May 2023 | A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants | |
| Phase 1Completed | 31 Aug 2023 | A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026